Calvo, E., López-Martin, J. A., Bendell, J., Eder, J. P., Taylor, M., Ott, P. A., … Antonia, S. J. (2015). 3098 Nivolumab (NIVO) monotherapy or in combination with ipilimumab (IPI) for treatment of recurrent small cell lung cancer (SCLC). In European Journal of Cancer (Vol. 51, pp. S633–S633). Elsevier BV. https://doi.org/10.1016/s0959-8049(16)31739-7

Calvo, E., J. A. López-Martin, J. Bendell, J. P. Eder, M. Taylor, P. A. Ott, M. C. Pietanza, et al. “3098 Nivolumab (NIVO) monotherapy or in combination with ipilimumab (IPI) for treatment of recurrent small cell lung cancer (SCLC).” In European Journal of Cancer, 51:S633–S633. Elsevier BV, 2015. https://doi.org/10.1016/s0959-8049(16)31739-7.

Calvo E, López-Martin JA, Bendell J, Eder JP, Taylor M, Ott PA, et al. 3098 Nivolumab (NIVO) monotherapy or in combination with ipilimumab (IPI) for treatment of recurrent small cell lung cancer (SCLC). In: European Journal of Cancer. Elsevier BV; 2015. p. S633–S633.

Calvo, E., et al. “3098 Nivolumab (NIVO) monotherapy or in combination with ipilimumab (IPI) for treatment of recurrent small cell lung cancer (SCLC).” European Journal of Cancer, vol. 51, Elsevier BV, 2015, pp. S633–S633. Crossref, doi:10.1016/s0959-8049(16)31739-7.

Calvo E, López-Martin JA, Bendell J, Eder JP, Taylor M, Ott PA, Pietanza MC, Horn L, Jäger D, Braud FD, Morse MA, Ascierto PA, Le DT, Amin A, Evans J, Simon J, Lin CS, Christensen O, Antonia SJ. 3098 Nivolumab (NIVO) monotherapy or in combination with ipilimumab (IPI) for treatment of recurrent small cell lung cancer (SCLC). European Journal of Cancer. Elsevier BV; 2015. p. S633–S633.